Published in J Am Coll Cardiol on January 22, 2008
NIPS to Identify High-risk Patients With ICD (NIPS-ICD) | NCT02373306
Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation (2010) 3.26
Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation (2010) 2.94
Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation (2009) 2.34
Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol (2012) 2.02
Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm (2015) 1.70
An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. Heart Rhythm (2010) 1.65
Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators. Circ Heart Fail (2015) 1.53
Sudden cardiac death: epidemiology and risk factors. Nat Rev Cardiol (2010) 1.53
Clinical practice of defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II registry. Europace (2010) 1.45
Enhanced risk profiling of implanted defibrillator shocks with circulating SCN5A mRNA splicing variants: a pilot trial. J Am Coll Cardiol (2014) 1.42
Selection of high-risk patients for device intervention with the new advances in technology. J Electrocardiol (2012) 1.39
Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail (2009) 1.24
Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes (2015) 1.18
ICDs at higher age and clinical risk factors. Neth Heart J (2014) 1.13
A new electrocardiogram marker to identify patients at low risk for ventricular tachyarrhythmias: sum magnitude of the absolute QRST integral. J Electrocardiol (2010) 1.07
Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift. J Interv Card Electrophysiol (2012) 1.04
Ventricular arrhythmia is predicted by sum absolute QRST integralbut not by QRS width. J Electrocardiol (2010) 1.02
Competing risk and heterogeneity of treatment effect in clinical trials. Trials (2008) 1.01
Incidence and risk factors of ventricular fibrillation before primary angioplasty in patients with first ST-elevation myocardial infarction: a nationwide study in Denmark. J Am Heart Assoc (2015) 1.00
Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: results from the NCDR. Heart Rhythm (2014) 0.99
Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR. Circ Cardiovasc Qual Outcomes (2013) 0.94
Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. J Am Heart Assoc (2015) 0.94
Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry. J Am Coll Cardiol (2010) 0.92
Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest? Neth Heart J (2009) 0.90
Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace (2008) 0.89
Prediction of sudden cardiac death: next steps in pursuit of effective methodology. J Interv Card Electrophysiol (2011) 0.89
A contemporary assessment of the risk for sudden cardiac death in patients with congenital heart disease. Pediatr Cardiol (2012) 0.86
Do implantable defibrillators help patients with CKD? Am J Kidney Dis (2014) 0.85
Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). Circ Arrhythm Electrophysiol (2014) 0.85
Primary prevention with ICDs, are we on the right track? Neth Heart J (2009) 0.84
Spatial/Frontal QRS-T Angle Predicts All-Cause Mortality and Cardiac Mortality: A Meta-Analysis. PLoS One (2015) 0.82
National Trends in the Use of Cardiac Resynchronization Therapy With or Without Implantable Cardioverter-Defibrillator. Circulation (2015) 0.82
The Wearable Cardioverter/Defibrillator - Toy Or Tool? J Atr Fibrillation (2016) 0.82
Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure. Am Heart J (2008) 0.81
Sudden cardiac death risk stratification. Circ Res (2015) 0.81
A call for re-evaluation of the guidelines for prophylactic ICD implantation. Neth Heart J (2014) 0.79
Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death: Prevalence and Impact on Mortality. Circ Cardiovasc Qual Outcomes (2015) 0.78
A combined anatomic and electrophysiologic substrate based approach for sudden cardiac death risk stratification. Am Heart J (2013) 0.78
Volumetric left ventricular ejection fraction is superior to 2-dimensional echocardiography for risk stratification of patients for primary prevention implantable cardioverter-defibrillator implantation. Am J Cardiol (2013) 0.78
Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality. Circ Cardiovasc Imaging (2017) 0.77
Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators. Europace (2015) 0.77
Electrocardiographic Markers and the Left Ventricular Ejection Fraction have Cumulative Effects on Risk of Sudden Cardiac Death. JACC Clin Electrophysiol (2015) 0.77
The 12-lead electrocardiogram and risk of sudden death: current utility and future prospects. Europace (2015) 0.77
Implantable cardioverter-defibrillators: indications and unresolved issues. Tex Heart Inst J (2012) 0.77
ECG quantification of myocardial scar and risk stratification in MADIT-II. Ann Noninvasive Electrocardiol (2013) 0.76
Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA. Appl Health Econ Health Policy (2016) 0.76
[ICD therapy in the primary prevention of sudden cardiac death: Risk stratification and patient selection]. Herzschrittmacherther Elektrophysiol (2015) 0.76
Prognostic value of non-invasive coronary computed tomography angiography: where are we now? Int J Cardiovasc Imaging (2010) 0.75
Polymorphisms in the GNAS Gene as Predictors of Ventricular Tachyarrhythmias and Sudden Cardiac Death: Results From the DISCOVERY Trial and Oregon Sudden Unexpected Death Study. J Am Heart Assoc (2016) 0.75
Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death. Circ Arrhythm Electrophysiol (2016) 0.75
Electrocardiographic predictors of mortality and sudden cardiac death in patients with end stage renal disease on hemodialysis. J Electrocardiol (2016) 0.75
Treatment benefit and treatment harm rate to characterize heterogeneity in treatment effect. Biometrics (2013) 0.75
Device therapies: new indications and future directions. Curr Cardiol Rev (2015) 0.75
Attitudes of older adults with serious competing health risks toward their implantable cardioverter-defibrillators: a pilot study. BMC Geriatr (2015) 0.75
T-wave loop area from a pre-implant 12-lead ECG is associated with appropriate ICD shocks. PLoS One (2017) 0.75
Selecting patients for an implantable cardioverter-defibrillator: can the genie be put back into the bottle? J Am Coll Cardiol (2008) 0.75
A Questionable Indication For ICD Extraction After Successful VT Ablation. J Atr Fibrillation (2015) 0.75
Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention. Arrhythm Electrophysiol Rev (2012) 0.75
How To Better Identify Patients That Do Not Benefit From Prophylactic ICD Therpy. J Atr Fibrillation (2014) 0.75
When to implant an ICD following a myocardial infarction? Heart Rhythm (2013) 0.75
Do elderly patients benefit from implantable-cardioverter defibrillators? Neth Heart J (2014) 0.75
SCN5A splicing variants and the possibility of predicting heart failure-associated arrhythmia. Expert Rev Cardiovasc Ther (2013) 0.75
Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification. Heart (2016) 0.75
Influence of renal function on mortality and ventricular arrhythmias in patients undergoing first implantable cardioverter-defibrillator generator replacement. J Cardiovasc Electrophysiol (2015) 0.75
Who benefits from implantable cardioverter defibrillator therapy, and who pays the price? Neth Heart J (2013) 0.75
Influence of time between last myocardial infarction and prophylactic implantable defibrillator implant on device detections and therapies. "Routine Practice" data from the SEARCH MI registry. BMC Cardiovasc Disord (2012) 0.75
Subject of the year: who are we missing, who are we overtreating, and who is best served? Refining the prescription of implantable cardioverter-defibrillator therapy. J Interv Card Electrophysiol (2009) 0.75
Cardiac resynchronization therapy in ischemic and non-ischemic cardiomyopathy. J Arrhythm (2017) 0.75
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. J Am Coll Cardiol (2017) 0.75
[ICD therapy for the primary prevention of sudden cardiac arrest. The patient after a myocardial infarction]. Herzschrittmacherther Elektrophysiol (2010) 0.75
Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clin Res Cardiol (2017) 0.75
Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure. Heart Fail Rev (2016) 0.75
Identifying patients with less potential to benefit from implantable cardioverter-defibrillator therapy: comparison of the performance of four risk scoring systems. J Interv Card Electrophysiol (2017) 0.75
Implantable cardioverter-defibrillator elective generator replacement: a procedure for all? J Interv Card Electrophysiol (2016) 0.75
Elevated γ-glutamyltransferase in implantable cardioverter defibrillator patients. Wien Klin Wochenschr (2011) 0.75
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71
Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63
Log transformation: application and interpretation in biomedical research. Stat Med (2012) 4.18
Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell (2006) 4.13
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13
Long QT syndrome. J Am Coll Cardiol (2008) 4.08
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation (2004) 3.78
Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol (2003) 3.05
Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 3.03
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Free radicals, antioxidants in disease and health. Int J Biomed Sci (2008) 2.89
Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88
Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol (2011) 2.84
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 2.68
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol (2004) 2.63
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol (2005) 2.62
Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J (2007) 2.61
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
The influence of public reporting of outcome data on medical decision making by physicians. Arch Intern Med (2005) 2.40
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol (2008) 2.39
Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 2.32
Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol (2012) 2.31
Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation (2011) 2.26
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22
Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm (2013) 2.22
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Cardiovascular effects associated with air pollution: potential mechanisms and methods of testing. Inhal Toxicol (2002) 2.19
ECGScan: a method for conversion of paper electrocardiographic printouts to digital electrocardiographic files. J Electrocardiol (2005) 2.17
Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol (2011) 2.15